Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of FORMA Therapeutics patents

Patents where

Current Assignee

Name

FORMA Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10112915 3-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors	Patent 10112915 was granted and assigned to FORMA Therapeutics on October, 2018 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10112915	October 30, 2018
‌ US Patent 11649242 Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators	Patent 11649242 was granted and assigned to FORMA Therapeutics on May, 2023 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	11649242	May 16, 2023
‌ US Patent 10208052 Compositions for activating pyruvate kinase	Patent 10208052 was granted and assigned to FORMA Therapeutics on February, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10208052	February 19, 2019
‌ US Patent 10005734 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors	Patent 10005734 was granted and assigned to FORMA Therapeutics on June, 2018 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10005734	June 26, 2018
‌ US Patent 11247987 Inhibiting ubiquitin specific peptidase 30	Patent 11247987 was granted and assigned to FORMA Therapeutics on February, 2022 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	11247987	February 15, 2022
‌ US Patent 10550098 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors	Patent 10550098 was granted and assigned to FORMA Therapeutics on February, 2020 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10550098	February 4, 2020
‌ US Patent 10377773 Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors	Patent 10377773 was granted and assigned to FORMA Therapeutics on August, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10377773	August 13, 2019
‌ US Patent 10214500 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors	Patent 10214500 was granted and assigned to FORMA Therapeutics on February, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10214500	February 26, 2019
‌ US Patent 10377726 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors	Patent 10377726 was granted and assigned to FORMA Therapeutics on August, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10377726	August 13, 2019
‌ US Patent 10377767 Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors	Patent 10377767 was granted and assigned to FORMA Therapeutics on August, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10377767	August 13, 2019
‌ US Patent 10555935 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors	Patent 10555935 was granted and assigned to FORMA Therapeutics on February, 2020 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10555935	February 11, 2020
‌ US Patent 10214501 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors	Patent 10214501 was granted and assigned to FORMA Therapeutics on February, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10214501	February 26, 2019
‌ US Patent 10351571 Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors	Patent 10351571 was granted and assigned to FORMA Therapeutics on July, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10351571	July 16, 2019
‌ US Patent 10239845 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors	Patent 10239845 was granted and assigned to FORMA Therapeutics on March, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10239845	March 26, 2019
‌ US Patent 11396513 Compositions for activating pyruvate kinase	Patent 11396513 was granted and assigned to FORMA Therapeutics on July, 2022 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	11396513	July 26, 2022
‌ US Patent 10421732 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors	Patent 10421732 was granted and assigned to FORMA Therapeutics on September, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10421732	September 24, 2019
‌ US Patent 10519128 Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	Patent 10519128 was granted and assigned to FORMA Therapeutics on December, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10519128	December 31, 2019
‌ US Patent 10519127 Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	Patent 10519127 was granted and assigned to FORMA Therapeutics on December, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10519127	December 31, 2019
‌ US Patent 10519130 Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	Patent 10519130 was granted and assigned to FORMA Therapeutics on December, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10519130	December 31, 2019
‌ US Patent 10428031 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors	Patent 10428031 was granted and assigned to FORMA Therapeutics on October, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10428031	October 1, 2019
‌ US Patent 10442776 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors	Patent 10442776 was granted and assigned to FORMA Therapeutics on October, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10442776	October 15, 2019
‌ US Patent 10513507 Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	Patent 10513507 was granted and assigned to FORMA Therapeutics on December, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10513507	December 24, 2019
‌ US Patent 10508098 Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	Patent 10508098 was granted and assigned to FORMA Therapeutics on December, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10508098	December 17, 2019
‌ US Patent 10000495 Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors	Patent 10000495 was granted and assigned to FORMA Therapeutics on June, 2018 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10000495	June 19, 2018
‌ US Patent 10450284 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors	Patent 10450284 was granted and assigned to FORMA Therapeutics on October, 2019 by the United States Patent and Trademark Office.	FORMA Therapeutics	FORMA Therapeutics	United States Patent and Trademark Office	10450284	October 22, 2019

...

Results per page:

113 results

0 selected

113 results

0 selected